IWR-1, a tankyrase inhibitor, can hamper the expression of key stem markers in osteosarcoma, impair osteosarcoma CSC self-renewal and enhance doxorubicin sensitivity by affecting β-catenin translocation in vivo [148]. Here, TNKS is linked to osteosarcoma.